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Abstract
Background: Steatotic livers are vulnerable to the deleterious effects of ischaemia–reperfusion injury
(IRI) that occur after hepatic surgery. Ischaemic preconditioning (IPC) has been shown to abrogate the
effects of IRI in patients undergoing hepatic surgery. Experimental studies have suggested that IPC may
be beneficial in steatotic livers subjected to IRI.
Objective: The aim of this systematic review was to evaluate the effects of IPC on steatotic livers
following hepatic IRI in experimental models.
Methods: An electronic search of the OVID Medline and EMBASE databases was performed to identify
studies that reported clinically relevant outcomes in animal models of hepatic steatosis subjected to IPC
and IRI.
Results: A total of 1093 articles were identified, of which 18 met the inclusion criteria. There was
considerable heterogeneity in the type of animal model, and duration and type of IRI. Increased
macrovesicular steatosis (> 30%) was associated with a poor outcome following IRI. Ischaemic precon-
ditioning was found to be beneficial in > 30% steatotic livers and provided for decreased histological
damage, improved liver function findings and increased survival.
Conclusions: Experimental evidence supports the use of IPC in steatotic livers undergoing IRI. These
findings may be applicable to patients undergoing liver surgery. However, clinical studies are required to
validate the efficacy of IPC in this setting.
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Introduction
Ischaemia–reperfusion injury (IRI) is a phenomenon whereby
prolonged ischaemia and subsequent re-oxygenation lead to a
pathophysiological injury process.1 It is a major cause of liver
damage during hepatic surgery2,3 and occurs most frequently
during liver transplantation and resection. In liver resection,
in-flow vascular occlusion (the Pringle manoeuvre4) is used to
decrease blood loss intraoperatively, but may lead to warm IRI;
conversely, in orthotopic liver transplantation (OLT) the liver is
subjected to cold–rewarming IRI when the donor liver is
reperfused in the recipient.3 Ischaemia–reperfusion injury is asso-
ciated with numerous downstream sequelae and may ultimately
result in liver failure.2 This is particularly true in steatotic livers,
for which increased rates of graft failure have been described in
recipients of grafts with moderate-to-severe (≥ 30%) hepatic
steatosis.5,6 Complication rates post-liver resection have likewise
been reported to be two- or three-fold higher in this patient
group.7,8
A number of techniques have been developed to ameliorate the
detrimental physiological effects of IRI. One such strategy is
ischaemic preconditioning (IPC), which was first described in a
renal9 and subsequently in a cardiovascular10 model. Both cohorts
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demonstrated that a brief initial phase of ischaemia followed by
reperfusion (preconditioning) prior to a period of prolonged
ischaemia led to decreased tissue damage and enhanced func-
tional outcomes. Following this, the effects of IPC have been
investigated in other organ systems to assess whether it confers
similar benefits.1 The effects of IPC on the liver were first
described in 1993 with reference to the demonstration in an
animal model that occlusion of hepatic inflow for 5 min followed
by 10 min of reperfusion led to improved survival and hepatic
function following 90 min of ischaemia.11 These findings have
subsequently been replicated in human clinical studies.12,13
Conversely, the impact of IPC in steatotic livers is less well
elucidated, especially in the setting of OLT. The efficacy of IPC in
steatotic livers subjected to IRI was first described in 200014 and
the procedure has subsequently become an integral strategy for
attenuating IRI in experimental steatotic livers.15,16 There is
limited research to support the role of IPC clinically,17 and indeed
recent Cochrane reviews concluded that there is no evidence to
support or refute the use of IPC in liver resection or transplanta-
tion and that further studies are necessary.18,19
Despite continued interest in the potential benefits of IPC, there
has been no comprehensive overview of evidence evaluating its
impact on outcomes following IRI in experimental models of
hepatic steatosis. Defining this relationship is of critical impor-
tance in the formation of a framework for the further clinical
development of IPC. Therefore, the aims of this study were to
systematically review the literature and to provide a succinct
description of the impact of IPC on outcomes in experimental
studies of steatotic livers subjected to IRI.
Materials and methods
A systematic electronic search was conducted through the OVID
Medline and EMBASE databases from their inception to Septem-
ber 2012 according to Systematic Review Centre for Laboratory
Animal Experimentation (SYRCLE) recommendations.20,21 A
combination of keyword searches (.mp) and MeSH terms (/) was
used as follows: (ischaemic preconditioning.mp OR ischemic
preconditioning.mp OR Ischemic preconditioning/) AND
(liver.mp OR hepatic.mp OR Liver/ OR steatosis.mp OR exp Fatty
liver/). The search was limited to English-language articles. There
were no database-stipulated limits to ‘animal’ experimentation as
recommended by SYRCLE guidelines.20 This ensured that publi-
cations describing work in either human or animal models would
not be overlooked.
Inclusion criteria required that studies had investigated the
use of IPC in hepatic IRI in any animal model. Studies were
excluded if they: (i) did not represent original research (system-
atic reviews, narrative reviews, commentaries and editorials); (ii)
included subjects with non-alcoholic steatohepatitis (NASH)
rather than simple steatosis (NASH was defined as steatosis with
hepatocellular injury and inflammation without fibrosis22),
or (iii) did not report clinically relevant outcomes [graft or
recipient survival, histological findings or liver function test
(LFT) results].
The primary reviewer (MJJC) executed the searches, using titles
and abstracts to manually screen identified articles. Eligibility was
determined using a standardized proforma and data were subse-
quently extracted to an excel spreadsheet. Discrepancies were
adjudicated independently by the senior author (ASJRB). Dupli-
cates were excluded. Publications with overlapping study popula-
tions were filtered to include only the text with the largest number
of subjects. Information obtained included type of animal model,
severity and type of steatosis, duration of IPC, duration and type
of hepatic IRI (partial/total, warm/cold) and outcome (recipient
survival, histology or LFT results). Basic descriptive statistics were
used to summarize data for this systematic review. Tabulated
depictions of information were used when appropriate to facili-
tate ease of interpretation. For studies with incomplete study
details or outcome measures, the corresponding author was con-
tacted via e-mail for additional data. If data were presented
graphically, the authors were contacted for numerical values and if
these were not available, data were measured using digital image
analysis software (ImageJ; http://imagej.nih.gov/ij/). Results are
shown as the mean ± standard error of the mean (SEM).
The methodological quality of the included studies was assessed
using a 15-point rating system described by Wever et al.23 This was
tabulated separately for warm ischaemia–reperfusion and cold
preservation–reperfusion injury. If there was no discrepancy
between the number of animals described in the methods section
and the number stated in the figure legends or the results section,
it was assumed that no animals had been excluded from analysis.
The potential for publication bias was assessed by a search for
asymmetry in funnel plots for the different outcome measures.
Results
A total of 503 and 590 articles were identified in the Medline and
EMBASE databases, respectively. After the exclusion of duplicates,
1043 abstracts were screened and 18 full-text papers were acquired
for further evaluation. No additional studies were identified from
manual searches of the reference lists. All 18 studies met the inclu-
sion criteria (Fig. 1) and were included in the analysis. Among the
18 studies, 13 examined the impact of IPC in warm IRI15,16,24–34
(Table S1, online) and the remaining five studies investigated the
impact of IPC in cold IRI35–39 (Table S2, online). Experiments in
all 18 studies had been carried out using male rodents and none
had imposed any delay or interval between the IPC stimulus and
the IRI episode.
Warm IRI
Thirteen studies examined the effect of IPC on warm IRI in
steatotic livers.15,16,24–34 The majority were performed in rats or
mice (n = 12) and one had used a rabbit model. Eight studies used
a genetic model of hepatic steatosis;15,24,27–30,32,33 four studies used
dietary modifications so that steatosis was induced by either a
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choline-deficient diet (n = 2)31,34 or a high-cholesterol diet
(n = 2).25,26 One study had used both a genetic model (ob/ob
mouse) and choline-deficient diet-induced steatosis in C57
mice.16 Eleven of the 13 studies had included both sham (lapa-
rotomy only) and non-preconditioned steatotic livers as
controls.15,24–33 The remaining two studies had used non-
preconditioned steatotic livers as control livers.16,34
Moderate-to-severe (> 30%) steatosis was present in 12 of the
13 studies.15,16,24–31,33,34 One study reported mild (< 30%)
steatosis.32 Five studies investigated a predominance of
macrovesicular steatosis (MaS),24–26,32,33 five studies examined
mixed hepatic steatosis,15,27–30 two studies investigated a predomi-
nance of microvesicular steatosis (MiS)31,34 and one study16 inves-
tigated both types of steatosis independently.
Eight studies used 5-min ischaemia and 10-min reperfusion
(5 + 10) in their IPC protocol,24–31 three studies used 10-min
ischaemia16,32,34 and 10-min reperfusion (10 + 10) and one study
used 10-min ischaemia with 15-min reperfusion (10 + 15).33 One
study investigated all three durations of IPC experiment and used
non-preconditioned steatotic livers for comparison.15
All 13 studies used partial vascular occlusion to the median and
left liver lobes to induce ischaemia to 70% of the liver. To assess the
effect of IPC on survival rates, one study induced total hepatic
ischaemia27 and another study performed partial vascular occlu-
sion to 70% of the liver and resected the non-ischaemic lobes
(30% of the liver) at the onset of reperfusion.15 The most common
duration of warm ischaemia was 60 min (n = 7; range:
45–90 min). There was wide variation in the duration of
reperfusion (from 30 min to 24 h); the most common duration
was 24 h (seven of 13 studies). Studies that applied multiple
reperfusion end-points used non-preconditioned steatotic livers
as control material for each reperfusion end-point.15,16,24,28–30,34
Outcome measures included survival (n = 2) (Table 1), histo-
logical changes (n = 10) (Table 2) and LFT findings (n = 13)
(Table 3). Assessment of histological injury based on a point-
counting method15 was used in eight studies.15,24,27–30,32,33 Two
studies assessed the percentage of hepatocellular necrosis as the
histological end-point.16,34 Of the eight studies that described his-
tological assessment utilizing a point-counting method, seven
studies reported the percentage of Grade 3 necrosis within the
livers15,24,27–30,33 and the remaining study reported the average his-
tological injury score in each experimental group.32 In two of 10
studies, the histological assessment was blinded.32,33 Seven studies
used a commercial enzymatic kit to measure serum LFTs15,24,25,27–30
Potentially relevant abstracts identified
n = 1093
Abstracts excluded (n = 1075)
- Did not report IPC in
steatotic livers   
Not original research articles      
Clinical studies   
Duplicates    
Investigated NASH  
-
-
-
-
Manuscripts retrieved for detailed evaluation
n = 18
Manuscripts identified from searching
reference lists
n = 0
Potentially appropriate manuscripts
n = 18
Manuscripts excluded from
systematic review
n = 0
Manuscripts meeting the inclusion criteria
n = 18
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= 599
= 86
= 51
= 3
Figure 1 Quorum diagram. IPC, ischaemic preconditioning; NASH, non-alcoholic steatohepatitis
HPB 3
HPB 2015, 17, 1–10 © 2014 International Hepato-Pancreato-Biliary Association
and the remaining six studies used an automated biochemistry
analyser.16,26,31–34
The quality assessments of the included studies of warm IRI
are shown in Table S3 (online). The average score reported was
9/15 (67 ± 7%), the lowest was 8/14 (57%) and the highest was
12/15 (80%). Only two studies reported the randomization of
animals across treatment groups.30,32 There was no report of
allocation concealment in either study. Of the 12 studies that
reported histology outcome, only two (17%) stated that histo-
logical assessment was blinded.32,33 The other outcome measures
were not blinded in any of the studies included. There were no
reports of the exclusion of animals from analysis and only three
Table 1 Survival outcomes in experimental models of warm ischaemia–reperfusion injury and hepatic steatosis with ischaemic precondi-
tioning (IPC)
Authors Animal Steatosis
model
Steatosis,
%
Type of
steatosis
Duration of
IPC, min
Duration of
ischaemia,
min (type of
ischaemia)
Duration of
reperfusion
Survival of
preconditioned
(non-preconditioned)
steatotic livers
Serafin et al.27 Rat Genetic 60–70% Mixed 5 + 10a 60 (total) ≤ 30 days 70% (0%)b
Serafin et al.15 Rat Genetic 60–70% Mixed 5 + 10a 60 (total) ≤ 30 days 70% (0%)b
Mixed, presence of both macrovesicular and microvesicular steatosis.
a5 min total ischaemia + 10 min reperfusion.
bP < 0.05 versus non-preconditioned steatotic livers.
Table 2 Histological findings in experimental models of warm ischaemia–reperfusion injury and hepatic steatosis with ischaemic precondi-
tioning (IPC)
Authors Animal Steatosis
model
Steatosis,
%
Type of
steatosis
Duration of
IPC, min
Duration of
ischaemia,
min (type of
ischaemia)
Duration of
reperfusion
Results in preconditioned
(non-preconditioned)
steatotic livers
Steenks et al.32 Rat Genetic < 30% MaS 10 + 10a 45 (partial) 60 min Hepatic injury score:
1.6 ± 0.2 (1.3 ± 0.5)
Saidi et al.33 Rat Genetic 30–60% MaS 10 + 15b 75 (partial) 180 min Grade 3 necrosis: 15%
(55%)d
Tacchini et al.24 Rat Genetic 60–70% MaS 5 + 10c 60 (partial) 24 h Grade 3 necrosis: 70 ± 10%
(30 ± 5%)d
Serafin et al.27 Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 360 min
24 h
Grade 3 necrosis: 10 ± 5%
(35 ± 10%)d
Grade 3 necrosis:
27.5 ± 5% (75 ± 5%)d
Casillas-Ramirez
et al.28
Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 24 h Grade 3 necrosis: 30 ± 1%
(74 ± 1%)d
Massip-Salcedo
et al.29
Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 24 h Grade 3 necrosis: 28 ± 1%
(74 ± 1%)d
Massip-Salcedo
et al.30
Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 360 min
24 h
Grade 3 necrosis: 12 ± 1%
(35 ± 2%)d
Grade 3 necrosis: 24 ± 1%
(75 ± 2%)d
Serafin et al.15 Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 24 h Grade 3 necrosis: 30 ± 5%
(74 ± 5%)d
Selzner et al.34 Mouse CDD 70% MiS 10 + 10a 75 (partial) 24 h Grade 3 necrosis: 35 ± 10%
(70 ± 10%)d
Selzner et al.16 Mouse Genetic
or CDD
58% (genetic)
70% (CDD)
MaS
MiS
10 + 10a 45 (partial) 24 h Grade 3 necrosis: 24 ± 3%
(70 ± 8.5%)d
Grade 3 necrosis: 6 ± 0.2%
(26 ± 5%)d
a10 min total ischaemia + 10 min reperfusion.
b5 min total ischaemia + 15 min reperfusion.
c5 min total ischaemia + 10 min reperfusion.
dP < 0.05 versus non-preconditioned steatotic livers (results shown as mean ± standard error of the mean).
CDD, choline-deficient diet; MaS, macrovesicular steatosis; MiS, microvesicular steatosis; Mixed, presence of both macrovesicular and
microvesicular steatosis.
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of the 13 (23%) studies reported control of animal body
temperature.25,26,33
Cold IRI
Five studies examined the effect of IPC and cold IRI in steatotic
livers.35–39 All of these studies had been performed in a rodent
genetic model of hepatic steatosis (Zucker fa/fa). Four
studies36–39 used both sham (laparotomy only) and non-
preconditioned steatotic livers and one used non-preconditioned
steatotic livers as control livers.35 Four studies36–39 reported on
moderate (30–60%) mixed steatosis and one study described
minimal to no hepatic steatosis.35 Four studies used 5 + 10
Table 3 Liver function tests in experimental models of warm ischaemia–reperfusion injury and hepatic steatosis with to ischaemic precon-
ditioning (IPC)
Authors Animal Steatosis
model
Steatosis,
%
Type of
steatosis
Duration of
IPC, min
Duration of
ischaemia,
min (type of
ischaemia)
Duration of
reperfusion
Results in preconditioned
(non-preconditioned)
steatotic livers
Steenks et al.32 Rat Genetic < 30% MaS 10 + 10a 45 (partial) 60 min ALT: 4100 ± 1500
(2500 ± 200 U/l)
AST: similar to ALT findings
Saidi et al.33 Rat Genetic 30–60% MaS 10 + 15b 75 (partial) 180 min AST: 3285 ± 122.3
(5436.3 ± 984.7 U/l)d
Koti et al.26 Rat HC 30–60% MaS 5 + 10c 45 (partial) 120 min ALT: 474.8 ± 122.3
(5436.3 ± 984.7 U/l)d
AST: 630.8 ± 76.9
(3166.3 ± 379.6 U/l)d
Hafez et al.25 Rabbit HC 40–60% MaS 5 + 10c 60 (partial) 420 min ALT: 54 ± 14 (178 ± 34 IU/l)d
AST: 199 ± 33 (406 ± 86
IU/l)d
Tacchini et al.24 Rat Genetic 60–70% MaS 5 + 10c 60 (partial) 360 min
24 h
ALT: 675 ± 100 (400 ± 50
U/l)d
ALT: 152 ± 51 (405 ± 101
U/l)d
Serafin et al.27 Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 360 min ALT: 205 ± 53
(1003 ± 152 U/l)d
Casillas-Ramirez
et al28
Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 24 h ALT: 310 ± 49
(2708 ± 301 U/l)d
Massip-Salcedo
et al.29
Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 24 h ALT: 408 ± 59
(2505 ± 310 U/l)d
Massip-Salcedo
et al.30
Rat Genetic 60–70% Mixed 5 + 10c 60 (partial) 360 min
24 h
ALT: 180 ± 21
(3502 ± 501 U/l)d
ALT: 255 ± 110
(2502 ± 508 U/l)d
Serafin et al.15 Rat Genetic 60–70% Mixed 5 + 10c
10 + 10a
10 + 15b
60 (partial) 24 h ALT: 153 ± 23 (405 ± 75 U/l)d
ALT: 370 ± 102 U/l
ALT: 273 ± 25 U/ld
Rolo et al.31 Rat CDD 70% MiS2 5 + 10c 90 (partial) 720 min ALT: 705 ± 18 (1801 ± 10
IU/l)d
AST: 953 ± 102
(1802 ± 203 IU/l)d
Selzner et al.34 Mouse CDD 70% MiS 10 + 10a 75 (partial) 240 min
24 h
AST: 8010 ± 1008
(15508 ± 501 U/l)d
AST: 4008 (13510 ± 2050
U/l)d
Selzner et al.16 Mouse Genetic
or CDD
58% (genetic)
70% (CDD)
MaS
MiS
10 + 10a 45 (partial) 24 h AST: 13620 ± 4692
(19940 ± 4471 U/l)
AST: 3975 ± 869
(8025 ± 998 U/l)d
a10 min total ischaemia + 10 min reperfusion.
b5 min total ischaemia + 15 min reperfusion.
c5 min total ischaemia + 10 min reperfusion.
dP < 0.05 versus non-preconditioned steatotic livers (results shown as mean ± standard error of the mean).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CDD, choline-deficient diet; HC, high cholesterol; MaS, macrovesicular steatosis;
MiS, microvesicular steatosis; Mixed, presence of both macrovesicular and microvesicular steatosis.
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IPC36–39 and one study used 10 + 10 IPC prior to cold ischae-
mia.35 Following cold ischaemia, livers were reperfused in vivo
using an OLT model in all studies. The durations of cold ischae-
mia used were 240 min (n = 1) or 360 min (n = 4). The organs
were flushed with University of Wisconsin (Madison, WI, USA)
solution in all studies and stored for the duration of cold ischae-
mia at 4 °C on ice.
Outcome measures included survival (n = 2) (Table 4), histol-
ogy (n = 4) (Table 5) and LFT findings (n = 4) (Table 6). All four
of the studies that assessed histological injury used a point-
counting method15 and none of the observers were blinded. Two
of the studies reported only the severity of necrosis and two
studies reported average histological injury scores. In all four
studies, commercial enzymatic kits were used to measure liver
function.
The quality assessments of the included studies for cold IRI
are shown in Table S4 (online). The average score reported was
10/14 (74 ± 7%); four studies at the lower end scored 10/14
(71%) and one study achieved a high score of 12/14 (86%). All
five studies randomized animals across the treatment groups,
but only one reported the concealment of allocation in the
study; furthermore, only one study stated that histological
assessment was blinded. No animals were excluded from analysis
and none of the five studies reported the control of animal body
temperature.
Analysis
Impact of IPC in steatotic livers subjected to warm IRI
Both of the studies that reported on mortality demonstrated
increased 30-day survival in animals that were subjected to 5 + 10
preconditioning compared with non-preconditioned animals
(Table 1).15,27 Histologically, preconditioning was associated with
decreased necrosis compared with that in non-preconditioned
steatotic livers (Table 2).15,16,24,27–30,33,34 In concordance with histo-
logical findings, LFT [alanine aminotransferase/aspartate amino-
transferase (ALT/AST)] results were lower in preconditioned
animals than in non-preconditioned animals (Table 3).15,24–31,33,34
One study showed no difference in post-reperfusion ALT
between animals subjected to 10 + 10 preconditioning and non-
preconditioned animals15 and another showed decreased AST
in preconditioned animals with MiS but only a trend towards
decreased AST in animals with MaS.16 A single study found
evidence of increased histological damage and reduced liver func-
tion in preconditioned steatotic livers compared with non-
preconditioned steatotic livers.32 Funnel plot assessment
demonstrated that negative studies appeared to be under-
represented for histology and LFT results (data not shown).
Impact of IPC in steatotic livers subjected to cold IRI
In both studies that reported mortality, recipients of precondi-
tioned steatotic grafts achieved significantly improved rates of
Table 4 Survival outcome in experimental models of orthotopic liver transplantation and hepatic steatosis with ischaemic preconditioning
(IPC)
Authors Animal Steatosis
model
Steatosis,
%
Type of
steatosis
Duration of
IPC, min
Duration of
ischaemia,
min (perfusate)
Duration of
reperfusion
Survival of
preconditioned
(non-preconditioned)
steatotic livers
Niemann et al.35 Rat Genetic < 10% Minimal 10 + 10a 240 (UW) 24 h 87.5% (25%)c
Jimenez-Castro et al.36 Rat Genetic 40–60% Mixed 5 + 10b 360 (UW) 14 days 70% (30%)c
a10 min total ischaemia + 10 min reperfusion.
b5 min total ischaemia + 10 min reperfusion.
cP < 0.05 versus non-preconditioned steatotic livers.
Mixed, presence of both macrovesicular and microvesicular steatosis; UW, University of Wisconsin solution.
Table 5 Histological findings in experimental models of orthotopic liver transplantation and hepatic steatosis with ischaemic preconditioning
(IPC)
Authors Animal Steatosis
model
Steatosis,
%
Type of
steatosis
Duration of
IPC, min
Duration of
ischaemia,
min (perfusate)
Duration of
reperfusion
Results in
preconditioned
(non-preconditioned)
steatotic livers
Jimenez-Castro
et al.36
Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min Hepatic injury score:
1.4 ± 0.2 (3.8 ± 0.1)b
Casillas-Ramirez
et al.37
Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min Hepatic injury score:
1.4 ± 0.2 (3.8 ± 0.1)b
Carrasco-Chaumel
et al.38
Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min Grade 3 necrosis: 25 ± 1%
(65 ± 1%)b
Fernandez et al.39 Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min ↓Severity of necrosis
a5 min total ischaemia + 10 min reperfusion.
bP < 0.05 versus non-preconditioned steatotic livers (results shown as mean ± standard error of the mean).
Mixed, presence of both macrovesicular and microvesicular steatosis; UW, University of Wisconsin solution.
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survival compared with recipients of non-preconditioned
steatotic grafts (Table 4).35,36 Likewise, recipients of precondi-
tioned steatotic grafts achieved lower LFT results and showed
decreased necrosis on histology (Tables 5 and 6).36–39 There were
no negative findings on the effects of IPC on steatotic livers sub-
jected to cold IRI.
Discussion
Ischaemia–reperfusion injury initiates a sequence of events that
lead to cellular damage2 and is a major cause of morbidity and
mortality in liver surgery. During liver resection, the Pringle
manoeuvre is used to decrease blood loss, but it induces IRI that
may impair liver regeneration.40 In OLT, it is mandatory for the
organ to undergo IRI in the form of cold ischaemia during organ
preservation and subsequent warm reperfusion.3 This has led to
the development of strategies such as IPC to mitigate the deleteri-
ous effects of IRI. Although IPC has been shown to be protective
against IRI,1 its impact on steatotic livers subjected to IRI is less
evident. Given that hepatic steatosis is associated with consistently
poorer functional outcomes following liver surgery and an
increased susceptibility to IRI,6,8 there is a need for effective strat-
egies to reduce IRI in steatotic livers. The present review demon-
strates that in experimental models of hepatic steatosis, animals
with preconditioned livers have improved outcomes following
IRI, with increased survival, decreased histological damage and
improved liver function.
The majority of studies identified in this review used genetically
modified animals to model hepatic steatosis. However, the
pathophysiological defect used to induce this condition (leptin or
leptin receptor deficiency) does not accurately reflect the aetiology
that underpins clinical hepatic steatosis.41 Similarly, animals fed
on a choline-deficient diet developed significant weight loss and
insulin sensitivity and therefore do not represent a true reflection
of this condition.41 It is proposed that a high-fat and high-
carbohydrate diet model would most closely emulate steatosis in
the clinical setting. Indeed, this was most closely approximated in
two of the studies identified, which used a high-cholesterol
diet.25,26 However, it is acknowledged that a single model encom-
passing the full characteristics of human hepatic steatosis remains
elusive and future studies must pay close consideration to animal
diet to ensure clinical relevance.
Hepatic steatosis is categorized as mild, moderate or severe
according to whether < 30%, 30–60% or > 60%, respectively, of
hepatocytes contain cytoplasmic fat vacuoles.42 Additionally,
hepatic steatosis is described qualitatively according to the type
(MaS or MiS) of steatosis present: MaS is thought to be associated
with metabolic syndrome or alcohol abuse, and MiS is typically
related to toxins or metabolic disorders.42 The presence of MaS
alone is rare, and usually both types of steatosis are present.42 In
the 18 studies identified, moderate-to-severe steatosis was present
in 15 studies and mixed hepatic steatosis was present in 12 studies.
Histological heterogeneity among studies makes the generaliza-
tion of data difficult and there continues to be much controversy
on the propriety of individual staining methods and whether
histological diagnosis represents a reference-standard method.43
This has remained a major obstacle in efforts to make detailed
comparisons between experimental and clinical models of IRI.
Table 6 Liver function tests in experimental models of orthotopic liver transplantation and hepatic steatosis with ischaemic preconditioning
(IPC)
Authors Animal Steatosis
model
Steatosis,
%
Type of
steatosis
Duration of
IPC, min
Duration of
ischaemia,
min (perfusate)
Duration of
reperfusion
Results in
preconditioned
(non-preconditioned)
steatotic livers
Jimenez-Castro
et al.36
Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min ALT: 1100 ± 50
(4200 ± 450 IU/l)b
AST: 1200 ± 100
(3300 ± 400 IU/l)b
Casillas-Ramirez
et al.37
Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min ALT: 1050 ± 100
(4350 ± 500 IU/l)b
AST: 1250 ± 150
(3400 ± 550 IU/l)b
Carrasco-Chaumel
et al.38
Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min ALT: 500 ± 100
(2800 ± 500 U/l)b
AST: 500 ± 50
(3250 ± 500 U/l)b
Fernandez et al.39 Rat Genetic 40–60% Mixed 5 + 10a 360 (UW) 240 min ALT: 600 ± 100
(3000 ± 300 U/l)b
AST: 350 ± 50
(4000 ± 600 U/l)b
a5 min total ischaemia + 10 min reperfusion.
bP < 0.05 versus non-preconditioned steatotic livers (results shown as mean ± standard error of the mean).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Mixed, presence of both macrovesicular and microvesicular steatosis; UW,
University of Wisconsin solution.
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The studies referred to in this review used three different dura-
tions of IPC, although the majority of studies (n = 12) used a
5 + 10 IPC protocol. This is perhaps not as concerning as the
histological differences among the studies because it reflects
the variability with which IPC is utilized clinically.12,44 Similarly,
the duration of warm ischaemia was variable (45–90 min), but all
studies used partial vascular occlusion as the preferred method of
inducing warm IRI. Studies that assessed survival used total
hepatic ischaemia.15,27 In the clinical setting, total in-flow occlu-
sion is the method most commonly utilized in liver surgery, but
this is poorly tolerated in rodents as a result of splanchnic con-
gestion and potential confounding from early bowel ischaemia
and consequent haemodynamic instability. Furthermore, there
was large variation in the duration of reperfusion in the studies of
warm IRI (30 min to 24 h). In studies of cold IRI, there was similar
variability in the duration of ischaemia and reperfusion. The dif-
ferences in duration of IPC, method and duration of IRI appear to
be based on laboratory experience and preference, but this pre-
cludes the objective comparison of data among studies. Although
it would be expedient to standardize IPC and IRI protocols in
future studies, it is acknowledged that multiple factors must be
considered in the selection of an experimental model of IRI.45
Survival rates of severely steatotic livers subjected to warm IRI
were very poor: none survived 60 min of total hepatic ischae-
mia.15,27 This is consistent with clinical observations, in which
patients with > 30% steatosis have an increased risk for postop-
erative morbidity and mortality.7,8 However, 5 + 10 IPC improved
survival rates to 70% in both of the studies that used this proto-
col,15,27 indicating that IPC was able to decrease liver damage and
preserve the functional capacity of the steatotic liver. Moreover,
survival rates of recipients of transplanted non-preconditioned
steatotic livers were very low and IPC significantly improved sur-
vival rates.35,36 This mirrors the findings of Jassem et al.,46 who
reported that IPC in deceased donor allografts was associated with
a promotion of genes involved in cellular protection and repair.
The use of IPC in steatotic livers was also associated with
decreased histological damage and improved liver function. Thir-
teen studies investigated warm IRI and reported LFT findings.
Twelve of these studies reported that IPC was associated with
decreases in ALT and AST compared with levels in non-
preconditioned steatotic livers15,16,24–31,33,34 and the remaining study
found increased transaminases in preconditioned steatotic livers
compared with non-preconditioned livers.32 In the four studies of
cold IRI in which LFT data were reported, IPC was associated with
decreased transaminases in preconditioned steatotic livers.36–39
Interestingly, one study showed that in warm IRI, 10 + 15 and
5 + 10 IPC protocols were associated with lower ALT, but 10 + 10
IPC was not.15 With regard to the impact of IPC on the type of
steatosis, Selzner et al. showed a significant benefit of 10 + 10 IPC
in MiS, but found the improvement was not statistically signifi-
cant in MaS.16 Importantly, this study16 was performed using a
mouse model; none of the studies made a direct comparison
between MiS and MaS using a rat or large animal model.
(However, other studies clearly showed a significant benefit of IPC
in MaS.24–26) Consistent with these LFT findings, histological
assessment showed that IPC led to decreased necrosis post-warm
IRI in nine studies15,16,24,27–30,33,34 and one study showed a non-
significant trend towards increased hepatic injury.32 Similar find-
ings were reported in preconditioned steatotic livers subjected
to cold IRI with decreased necrosis compared with non-
preconditioned livers.36–39
The methodological qualities of the animal studies included in
this review were comparable with those of a similar recently pub-
lished systematic review.23 However, there are a few aspects that
might be improved to better align with the principles of good
scientific practice and to decrease bias. Firstly, a distinct lack of
randomization was observed in studies investigating warm IRI,
which was compounded by the absence of outcome assessment
blinding in both IRI models. There was also no extraneous control
of animal body temperature. These issues diminish the scientific
and translational value of affected studies. Secondly, there is little
consensus on the optimal animal model for this particular field of
research, which is clearly apparent in the considerable variation in
both the animal models of hepatic steatosis and the histological
reporting of steatosis observed in this review. This significant
heterogeneity (in animals used, types and models of hepatic
steatosis, durations of IPC, ischaemia and reperfusion, and
outcome measures) limits the ability to uniformly appraise and
meta-analyse data, and instead forces greater focus on study con-
clusions. There is a clear need for the better reporting of outcomes
in animal studies in this field in order to provide a common
platform of results and to minimize potential bias in future studies.
Finally, the under-representation of negative findings in this field
may be attributed to publication bias resulting from a reluctance to
publish negative results or the lack of a forum in which to do so. It
is hoped that this systematic review will serve as a stimulus for the
stipulation that future animal studies should apply methodological
standards similar to those required in clinical research.
The articles identified in this systematic review demonstrate
that IPC was able to attenuate the negative effects of IRI in
steatotic livers as evidenced by decreased histological damage, less
hepatocyte injury and improved survival in preconditioned livers.
These studies also confirmed that > 30% steatotic livers were more
susceptible to warm and cold IRI, which is consistent with clinical
observations.6,7 This review demonstrates that IPC may poten-
tially enlarge the available organ donor pool by conferring pro-
tective properties to marginal donor grafts. To date, the most
commonly used duration of IPC in the clinical environment is
10 + 10 min17 and it is recommended that future experimental
studies should use a protocol aligned with this. Similarly, the
duration of cold ischaemia in the studies identified was relatively
short and a recent study has recommended that organs with
> 30% steatosis can be used in OLT if other factors (donor age
< 40 years, cold ischaemic time of < 5 h, non-circulatory cause of
death) are controlled.47 Although clinical studies have shown
minimal to no benefit of IPC in steatotic livers subjected to cold
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ischaemia of > 6 h,48,49 these findings should be replicated in
experimental studies to better elucidate the underlying mecha-
nism of IPC in the prolonged cold storage of steatotic livers. The
mechanisms underpinning the effects of IPC have been reviewed
extensively elsewhere.1 Both experimental and clinical studies
have implicated a complex set of mediators and pathways, but the
exact nature of the relationships among these factors remains
unknown. Additionally, there have been conflicting clinical results
of IPC in warm IRI14,50 and transplantation.51,52 This has led to
ongoing debate about the utility of IPC in liver surgery, but the
clinical effect of IPC in steatotic livers is not well described.
Further studies of IPC in steatotic livers in a clinical context are
required and experimental studies should be performed in an
appropriate manner in order to increase current understanding of
this complex relationship.
Conclusions
The evidence from this systematic review suggests that IPC
confers a protective effect in experimental steatotic livers sub-
jected to IRI and results in improved survival, decreased histologi-
cal injury and an improved liver enzyme profile. Conflicting
results with the use of IPC during clinical trials of hepatic surgery
should lead to caution in any routine clinical application. Future
experimental studies should ideally emulate the clinical environ-
ment, in terms of hepatic model and method of performing IRI, to
further improve understanding of the mechanism underlying
IPC. This may, in turn, lead to the identification of a subset of
patients who may particularly benefit from IPC. Concurrent use
of pharmacological therapy and IPC may ultimately yield the
greatest improvement in patient outcomes, especially in the
setting of hepatic steatosis.
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